DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection
BALTIMORE and PALO ALTO, Calif., Oct. 4, 2023 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to detect cancer, announced today that the company will participate in multiple sessions at the HLTH 2023 conference in Las Vegas, Nevada, and the CHEST 2023 Annual Meeting in Honolulu, Hawai'i, both taking place October 8-11, 2023.
- DELFI's approach to early cancer detection applies advanced machine learning technology to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer.
- An oral presentation at CHEST will highlight new data from the DELFI-L101 Study, "DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study," a prospective, multicenter, case-control study among individuals eligible for lung cancer screening to train and independently validate the blood-based test for early cancer detection.
- Victor Velculescu, M.D., Ph.D., DELFI Founder and Chief Executive Officer, will deliver a science and technology presentation on the company's lung cancer early detection test.
- As part of the "Updates in Lung Cancer" session, Peter Mazzone, M.D., MPH, Director of the Lung Cancer Program and Lung Cancer Screening Program for the Respiratory Institute at the Cleveland Clinic and the principal investigator for DELFI's L101 study, will present new data from the study during an oral presentation.